Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cerilliant
Merck
McKesson
Federal Trade Commission
US Army
Farmers Insurance
Argus Health
Cantor Fitzgerald
Accenture

Generated: October 22, 2017

DrugPatentWatch Database Preview

Rempex Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for REMPEX PHARMS INC, and when can generic versions of REMPEX PHARMS INC drugs launch?

REMPEX PHARMS INC has one approved drug.

There are two US patents protecting REMPEX PHARMS INC drugs.

There are twenty patent family members on REMPEX PHARMS INC drugs in twenty countries.

Summary for Applicant: Rempex Pharms Inc

International Patents:20
US Patents:2
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rempex Pharms Inc
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe ► Subscribe
Rempex Pharms Inc
MINOCIN
minocycline hydrochloride
INJECTABLE;INJECTION050444-001Approved Prior to Jan 1, 1982RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Rempex Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,744,179Tetracycline compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Rempex Pharms Inc Drugs

Country Document Number Estimated Expiration
European Patent Office2568987► Subscribe
Japan6025712► Subscribe
Brazil112012028524► Subscribe
European Patent Office3135289► Subscribe
Russian Federation2012147527► Subscribe
Mexico2012012993► Subscribe
Hong Kong1180586► Subscribe
Australia2011252919► Subscribe
Singapore185513► Subscribe
Japan2013529201► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
Merck
Cipla
AstraZeneca
US Department of Justice
QuintilesIMS
Federal Trade Commission
UBS
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot